PLX Stock-Based Compensation
Protalix Biotherapeutics Inc · Stock-Based Compensation
PLX Stock-Based Compensation
Latest reported$2.26Mperiod ending
PLX TTM Stock-Based Comp ($0.00 → $2.26M)
TTM stock-based compensation
High-resolution chart · PNG
PLX stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 2,260,000 | |
| 2,289,000 | |
| 2,297,000 | |
| 2,219,000 | |
| 2,241,000 | |
| 2,812,000 | |
| 3,253,000 | |
| 3,966,000 | |
| 4,443,000 | |
| 3,883,000 | |
| 3,448,000 | |
| 2,620,000 | |
| 1,945,000 | |
| 1,795,000 | |
| 2,085,000 | |
| 1,964,000 | |
| 2,105,000 | |
| 2,395,000 | |
| 2,375,000 | |
| 2,971,000 | |
| 3,822,000 | |
| 3,511,000 | |
| 3,126,000 | |
| 2,348,000 | |
| 1,130,000 | |
| 976,000 | |
| 835,000 | |
| 1,017,000 | |
| 843,000 | |
| 742,000 | |
| 514,000 | |
| 142,000 | |
| 195,000 | |
| 281,000 | |
| 337,000 | |
| 514,000 | |
| 602,000 | |
| 731,000 | |
| 988,000 | |
| 1,148,000 | |
| 1,431,000 | |
| 1,758,000 | |
| 1,802,000 | |
| 1,978,000 | |
| 1,638,000 | |
| 991,000 | |
| 1,242,000 | |
| 1,319,000 | |
| 2,167,000 | |
| 3,392,000 | |
| 4,089,000 | |
| 5,139,000 | |
| 6,491,000 | |
| 8,989,000 | |
| 7,751,000 | |
| 6,221,000 | |
| 4,124,000 | |
| 773,000 | |
| 886,000 | |
| 1,125,000 | |
| 1,271,000 | |
| 1,240,000 | |
| 1,282,000 | |
| 1,568,000 | |
| 2,051,000 | |
| 2,505,000 | |
| 2,683,000 | |
| 5,073,000 | |
| 4,235,000 | |
| 3,533,000 | |
| 5,245,000 | |
| 13,019,000 | |
| 13,019,000 | |
| 13,019,000 | |
| 12,296,000 | |
| 4,872,000 | |
| 4,872,000 | |
| 4,872,000 | |
| 3,421,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |